Stock Price & Analysis

The S1 support level for SCYX Stock is $1.08 ,The R1 resistant level for SCYX Stock is $1.22.

As of the end of day on 2025-02-21, the price of SCYX Stock was $1.07.

The target price for SCYX Stock according to analyst rating is 8.00, with the highest price target at 8.00 and the lowest at 8.00. Analysts have a Moderate Buy rating on SCYX Stock overall.

The market cap of SCYX is $40.6M.

SCYNEXIS, Inc. is a biotechnology company. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. Its Ibrexafungerp has demonstrated activity against a large collection of medically relevant strains of Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera. The Company has received approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection), and for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC), respectively.

SCYX has a total of 29 employees.